it's a good problem watching one programme jump ahead of another (i know that was a few months back), but the once lead 'pain' programme is now in the middle of the pack.
Yet it is a programme with some massive commercial advantages should they get it some decent funding to clear any current obstructions and get it into the clinic.
Lest Prof Mallucci and her lab announce they've cracked the ddRNAi route to silencing PERK and are heading to the clinic for all the big CNS diseases. Two areas they've spent considerable time researching.
- Forums
- ASX - By Stock
- Ann: Annual Report to shareholders
it's a good problem watching one programme jump ahead of another...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)